68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer

Schollhammer, Romain; Gallerande, H. de Clermont; Robert, G.; Yacoub, M.; Vimont, Delphine; Hindié, Elif; Fernandez, Philippe; Morgat, Clément

doi:10.1097/rlu.0000000000002672

Cited by 9 publications

(9 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the setting of PCa staging, Schollhammer and colleagues reported a clinical case of a patient undergoing PET/CT scans with 68 Ga-PSMA, 68 Ga-RM2 and 18F-Choline, while Fassbender et al used 68 Ga-PSMA PET/CT and 68 Ga-Ga-RM2 PET/MRI to study eight patients with a primary diagnosis of PCa [15,24]. The same heterogeneity in terms of the type of scanners used for patients' scanning can be also observed in the few studies assessing the role of 68 Ga-PSMA and 68 Ga-DOTA-RM2 in patients with recurrent PCa.…”

Section: Discussionmentioning

confidence: 99%

Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients

et al. 2021

View full text Add to dashboard Cite

The aim of the present study is to investigate the synergic role of 68Ga-PSMA PET/MRI and 68Ga-DOTA-RM2 PET/MRI in prostate cancer (PCa) staging. We present pilot data on twenty-two patients with biopsy-proven PCa that underwent 68Ga-PSMA PET/MRI for staging purposes, with 19/22 also undergoing 68Gaa-DOTA-RM2 PET/MRI. TNM classification based on image findings was performed and quantitative imaging parameters were collected for each scan. Furthermore, twelve patients underwent radical prostatectomy with the availability of histological data that were used as the gold standard to validate intraprostatic findings. A DICE score between regions of interest manually segmented on the primary tumour on 68Ga-PSMA PET, 68Ga-DOTA-RM2 PET and on T2 MRI was computed. All imaging modalities detected the primary PCa in 18/19 patients, with 68Ga-DOTA-RM2 PET not detecting any lesion in 1/19 patients. In the remaining patients, 68Ga-PSMA and MRI were concordant. Seven patients presented seminal vesicles involvement on MRI, with two of these being also detected by 68Ga-PSMA, and 68Ga-DOTA-RM2 PET being negative. Regarding extraprostatic disease, 68Ga-PSMA PET, 68Ga-DOTA-RM2 PET and MRI resulted positive in seven, four and five patients at lymph-nodal level, respectively, and at a bone level in three, zero and one patients, respectively. These preliminary results suggest the potential complementary role of 68Ga-PSMA PET, 68Ga-DOTA-RM2 PET and MRI in PCa characterization during the staging phase.

show abstract

Section: Discussionmentioning

confidence: 99%

Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In the setting of PCa staging, Schollhammer and colleagues reported a clinical case of a patient undergoing PET/CT scans with 68 Ga-PSMA, 68 Ga-RM2 and 18 F-Choline, while Fassbender et al used 68 Ga-PSMA PET/CT and 68 Ga-Ga-RM2 PET/MRI to study eight patients with primary diagnosis of PCa [15,24]. The same heterogeneity in terms of type of scanners used for patients' scanning can be also observed in the few studies assessing the role 68 Ga-PSMA and 68 Ga-DOTA-RM2 in patients with recurrent…”

Section: Discussionmentioning

confidence: 99%

68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Staging of High-risk Prostate Cancer Patients: a Prospective Pilot Trial

Mapelli

Ghezzo

Gajate

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: The aim of the present study is to investigate the synergic role of 68Ga-PSMA PET/MRI and 68Ga-DOTA-RM2 PET/MRI in PCa staging. Methods: Fifteen patients with biopsy-proven PCa underwent both 68Ga-PSMA PET/MRI and 68Ga-DOTA-RM2 PET/MRI within one month. TNM classification based on image findings was performed and semi-quantitative PET and quantitative MRI parameters were collected for each scan. Finally, DICE score between regions of interest manually segmented on the primary tumor on 68Ga-PSMA PET, 68Ga-DOTA-RM2 PET and on T2 MRI was computed. Results: All imaging modalities detected the primary PCa in 15 patients, with slight differences regarding the multifocality of intra-prostatic findings. Two patients presented seminal vesicles involvement on MRI, one of these was also detected by 68Ga-PSMA, with no uptake on 68Ga-DOTA-RM2 images. Regarding extra prostatic disease, 68Ga-PSMA PET, 68Ga-DOTA-RM2 PET and MRI resulted positive in 6, 2 and 4 patients at lymph-nodal level, respectively, and at bone level in 2, 0 and 1 patients, respectively, with 68Ga-PSMA PET detecting more lesions compared to 68Ga-DOTA-RM2 PET. The different findings detected by 68Ga-PSMA PET and 68Ga-DOTA-RM2 PET might reflect the complementary role of these radiotracers, as they detected different foci of intraprostatic disease, seminal vesicle invasion, lymph nodal and bone involvement. Conclusion: These preliminary results suggest a synergic role of 68Ga-PSMA PET, 68Ga-DOTA-RM2 PET and mpMRI in PCa characterization during the staging phase. (EudraCT: 2018-001034-18)

show abstract

“… 297 , 298 68 Ga-PSMA-11 (also called PSMA-HBED-CC) for PET is probably the tracer most often used for PCa. 299 – 301 Several 68 Ga-labeled PSMA ligands have been developed as theranostic agents, including 68 Ga-PSMA-617 and 68 Ga-PSMA-I&T. 302 – 304 The 18 F-labeled agents include 18 F-DCFBC, 18 F-DCFPyL, and 18 F-PSMA-1007, which exhibit many advantages such as a lower positron range and longer half-life compared with those of 68 Ga-labeled agents. 305 – 308 PSMA-based imaging has shown improved sensitivity and diagnostic accuracy in PCa.…”

Section: Targeting Psmamentioning

confidence: 99%

Targeting signaling pathways in prostate cancer: mechanisms and clinical trials

Xiao

et al. 2022

Sig Transduct Target Ther

100

View full text Add to dashboard Cite

Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding genomic landscapes and biological functions, the treatment of PCa continues to improve. Recently, various new classes of agents, which include next-generation androgen receptor (AR) signaling inhibitors (abiraterone, enzalutamide, apalutamide, and darolutamide), bone-targeting agents (radium-223 chloride, zoledronic acid), and poly(ADP-ribose) polymerase (PARP) inhibitors (olaparib, rucaparib, and talazoparib) have been developed to treat PCa. Agents targeting other signaling pathways, including cyclin-dependent kinase (CDK)4/6, Ak strain transforming (AKT), wingless-type protein (WNT), and epigenetic marks, have successively entered clinical trials. Furthermore, prostate-specific membrane antigen (PSMA) targeting agents such as 177Lu-PSMA-617 are promising theranostics that could improve both diagnostic accuracy and therapeutic efficacy. Advanced clinical studies with immune checkpoint inhibitors (ICIs) have shown limited benefits in PCa, whereas subgroups of PCa with mismatch repair (MMR) or CDK12 inactivation may benefit from ICIs treatment. In this review, we summarized the targeted agents of PCa in clinical trials and their underlying mechanisms, and further discussed their limitations and future directions.

show abstract

68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer

Cited by 9 publications

References 8 publications

Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients

Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients

68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Staging of High-risk Prostate Cancer Patients: a Prospective Pilot Trial

Targeting signaling pathways in prostate cancer: mechanisms and clinical trials

Contact Info

Product

Resources

About